500 patients67,039 observations150 daysLIVE

Patient P-03070

Synthetic patientONX-7 · Day 147 · 45–54 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
73%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S14
  2. Day 60 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 61 GI-04 recommendedGI Support Protocol GI-04
  4. Day 62 Patient acceptedStarted GI-04 in the companion
  5. Day 70 GI symptom burden −29% vs expectedGI Support Protocol GI-04
  6. Day 76 Tolerance state changedUnstable → Improving
  7. Day 80 ME-01 recommendedMonitoring Escalation ME-01
  8. Day 81 Patient acceptedStarted ME-01 in the companion
  9. Day 84 Deterioration detected before clinical escalationMonitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 60.

Primary contributors, last 14 days
  • GI instability+8
  • Nutritional resilience-7
  • Treatment adherence+4
  • Inflammatory activity+3
  • Toxicity-2

What helped?

  • GI Support Protocol GI-04Day 61
    Result: symptom burden −29%
  • Monitoring Escalation ME-01Day 80
    Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dosing / Timing Recommendation DT-01
72%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 83% showed improvement
  • median effect visible after 5 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Energy level
Daily log
3.9/10
worsening · -0.3 vs previous 14 d
Stress level
Daily log
5/10
worsening · +0.4 vs previous 14 d
Pessimism score
Daily log
5.2/10
worsening · +0.2 vs previous 14 d
Sleep quality
Wearable
29.5/100
worsening · -6.5 vs previous 14 d
Libido
Daily log
4.1/10
worsening · -0.2 vs previous 14 d
HRV
Wearable
52.8 ms
stable · -1.6 vs previous 14 d
Toxicity
Blood
35.4/100
improving · -3.6 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 35 from the failing basin, 54 from restoration.

Would help
  • DT-01 Dosing / Timing Recommendation
    83% improved among 12 similar · onset 5 d · confidence 72%
  • NP-02 Dietary Support Protocol
    57% improved among 14 similar · onset 10 d · confidence 72%
  • CR-01 Clinician Review
    100% improved among 5 similar · onset 5 d · confidence 72%
  • More protein
    GI -4.2 next day on high-intake days · n 19
Would not help
  • AD-05 Adherence Support
    only 18% improved among 11 similar
  • Keep fat low
    GI +4.1 next day on high-intake days · n 24
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Protein
    -4.2supporter · 95%
  • Dietary fat load
    +4.1detractor · 95%
  • Lactose
    +0.7no signal · 18%
  • Histamine load
    -0.6no signal · 15%
  • Alcohol
    -0.6no signal · 16%
  • Caffeine
    +0.2no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 30/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling 70
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 51
  • Autonomic recovery 40
    • Wearable3,925 steps/day
    • WearableShort sleep window
  • Mucosal barrier integrity 30
    • Daily logGI symptom score 55 and rising
    • WearableSleep 5.8 h, below personal baseline
DNA
Fictional pharmacogenomic panel
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Normal metabolizer
    Expected exposure
Microbiome
Shannon diversity 2 · butyrate capacity 30/100
  • Akkermansia muciniphilaNormal
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumLow
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
55 ms
Sleep
5.3 h
Steps
4,817
Resting HR
65 bpm
Daily log: GI score 55, nutritional resilience 42, adherence 50.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0314221%S1584
P-0318122%S0375
P-0313421%S0975
P-0341722%S0274
P-0311324%S08NP-02no change73
P-0302322%S1673
P-0326622%S0573
P-0341222%S1472
P-0331523%S0872
P-0334925%S1171
P-0327022%S1771
P-0334626%S17GI-04improved71